Latest & greatest articles for enalapril

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on enalapril or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on enalapril and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for enalapril

1. Enalapril

Enalapril Top results for enalapril - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search (...) button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for enalapril The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory

Trip Latest and Greatest2018

2. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.

Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. 27842179 2016 11 14 2017 02 03 2380-6591 2 1 2017 Jan 01 JAMA cardiology JAMA Cardiol Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF (...) is reduced by sacubitril/valsartan in comparison with enalapril. The PARADIGM-HF (Prospective Comparison of ARNI With an ACE-Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial randomly assigned 8399 patients with chronic HF, New York Heart Association class II to IV symptoms, and a left ventricular EF of 40% or less to treatment with enalapril 10 mg twice daily or sacubitril/valsartan 97/103 mg twice daily (previously known as LCZ696 [200 mg twice daily]) in addition

JAMA cardiology2016

3. Aliskiren, Enalapril, or Both in Heart Failure.

Aliskiren, Enalapril, or Both in Heart Failure. Aliskiren, Enalapril, or Both in Heart Failure. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27532843 Format MeSH and Other Data E-mail Subject Additional text (...) E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Aug 18;375(7):702. doi: 10.1056/NEJMc1606625. Aliskiren, Enalapril, or Both in Heart Failure. , , . Comment on [N Engl J Med. 2016] [N Engl J Med. 2016] PMID: 27532843 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH terms Substances Full Text Sources Medical PubMed Commons 0 comments How to cite this comment

NEJM2016

4. Aliskiren, Enalapril, or Both in Heart Failure.

Aliskiren, Enalapril, or Both in Heart Failure. Aliskiren, Enalapril, or Both in Heart Failure. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27532844 Format MeSH and Other Data E-mail Subject Additional text (...) E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Aug 18;375(7):701-2. doi: 10.1056/NEJMc1606625#SA1. Aliskiren, Enalapril, or Both in Heart Failure. 1 , 1 , 1 . 1 University of Brasilia, Brasilia, Brazil nevesfar@gmail.com. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID: 27532844 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text

NEJM2016 Full Text: Link to full Text with Trip Pro

5. Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure.

Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. BACKGROUND: Among patients with chronic heart failure, angiotensin-converting-enzyme (ACE) inhibitors reduce mortality and hospitalization, but the role of a renin inhibitor in such patients is unknown. We compared the ACE inhibitor enalapril with the renin inhibitor aliskiren (to test superiority or at least noninferiority) and with the combination of the two treatments (to test superiority) in patients with heart failure and (...) a reduced ejection fraction. METHODS: After a single-blind run-in period, we assigned patients, in a double-blind fashion, to one of three groups: 2336 patients were assigned to receive enalapril at a dose of 5 or 10 mg twice daily, 2340 to receive aliskiren at a dose of 300 mg once daily, and 2340 to receive both treatments (combination therapy). The primary composite outcome was death from cardiovascular causes or hospitalization for heart failure. RESULTS: After a median follow-up of 36.6 months

NEJM2016

6. PARADIGM?HF: Valsartan 160mg po BID + Sacubitril (=LCZ696) versus Enalapril 10mg po BID in Heart Failure

PARADIGM?HF: Valsartan 160mg po BID + Sacubitril (=LCZ696) versus Enalapril 10mg po BID in Heart Failure

RxFiles2016

7. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients

Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients 26022006 2015 08 08 2016 05 09 2015 08 08 1522-9645 36 30 2015 Aug 07 European heart journal Eur. Heart J. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. 1990-7 10.1093/eurheartj/ehv186 The angiotensin-receptor-neprilysin inhibitor (ARNI) LCZ696 reduced cardiovascular deaths and all (...) -cause mortality compared with enalapril in patients with chronic heart failure in the prospective comparison of ARNI with an Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial. To more completely understand the components of this mortality benefit, we examined the effect of LCZ696 on mode of death. PARADIGM-HF was a prospective, double-blind, randomized trial in 8399 patients with chronic heart failure, New York Heart

EvidenceUpdates2015

8. Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Angiotensin-neprilysin inhibition versus enalapril in heart failure. BACKGROUND: We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients. METHODS: In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice (...) daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes. RESULTS: The trial was stopped early, according to prespecified rules, after a median follow-up of 27 months, because the boundary for an overwhelming benefit with LCZ696 had been crossed. At the time

NEJM2014

9. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure.

Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. 25176015 2014 09 11 2014 09 16 2015 07 14 1533-4406 371 11 2014 Sep 11 The New England journal of medicine N. Engl. J. Med. Angiotensin-neprilysin inhibition versus enalapril in heart failure. 993-1004 10.1056/NEJMoa1409077 We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival (...) in such patients. In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes

NEJM2014

10. Losartan and enalapril are comparable in reducing proteinuria in children

Losartan and enalapril are comparable in reducing proteinuria in children 22739977 2012 11 08 2013 02 01 2015 11 19 1523-1755 82 7 2012 Oct Kidney international Kidney Int. Losartan and enalapril are comparable in reducing proteinuria in children. 819-26 10.1038/ki.2012.210 Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers delay progression of chronic kidney disease and have antiproteinuric effects beyond their effects on blood pressure. They are routinely (...) used in adults; however, their efficacy and safety in children, in whom the causes of chronic kidney disease are significantly different relative to adults, is uncertain. Here we assessed an open-label extension of a previous 3-month blinded trial, in which the efficacy and tolerability of losartan was compared to placebo or amlodipine in 306 normotensive and hypertensive children with proteinuria. In this study, 268 children were re-randomized to losartan or enalapril and followed until 100

EvidenceUpdates2013

11. Epaned (enalapril) for Oral Solution

Epaned (enalapril) for Oral Solution Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - EPANED (enalapril) for Oral Solution Company: Silvergate Pharmaceuticals, Inc. Application No.: 204308 Approval Date: 8/13/2013 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2013

12. Enalapril in Infants With Single Ventricle: Results of a Multicenter Randomized Trial

Enalapril in Infants With Single Ventricle: Results of a Multicenter Randomized Trial 20625111 2010 07 27 2010 09 13 2016 12 15 1524-4539 122 4 2010 Jul 27 Circulation Circulation Enalapril in infants with single ventricle: results of a multicenter randomized trial. 333-40 10.1161/CIRCULATIONAHA.109.927988 Angiotensin-converting enzyme inhibitor therapy improves clinical outcome and ventricular function in adults with heart failure. Infants with single-ventricle physiology have poor growth (...) and are at risk for abnormalities in ventricular systolic and diastolic function. The ability of angiotensin-converting enzyme inhibitor therapy to preserve ventricular function and improve somatic growth and outcomes in these infants is unknown. The Pediatric Heart Network conducted a double-blind trial involving 230 infants with single-ventricle physiology randomized to receive enalapril (target dose 0.4 mg . kg(-1) . d(-1)) or placebo who were followed up until 14 months of age. The primary end point

EvidenceUpdates2010 Full Text: Link to full Text with Trip Pro

13. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe: the HEALTH model

Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe: the HEALTH model Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe: the HEALTH model Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe: the HEALTH model Schwander B, Gradl B, Zollner Y, Lindgren P, Diener (...) HC, Luders S, Schrader J, Antonanzas Villar F, Greiner W, Jonsson B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of eprosartan and enalapril in the primary prevention

NHS Economic Evaluation Database.2009

14. Renal and retinal effects of enalapril and losartan in type 1 diabetes.

Renal and retinal effects of enalapril and losartan in type 1 diabetes. 19571282 2009 07 02 2009 07 07 2016 12 15 1533-4406 361 1 2009 Jul 02 The New England journal of medicine N. Engl. J. Med. Renal and retinal effects of enalapril and losartan in type 1 diabetes. 40-51 10.1056/NEJMoa0808400 Nephropathy and retinopathy remain important complications of type 1 diabetes. It is unclear whether their progression is slowed by early administration of drugs that block the renin-angiotensin system (...) . We conducted a multicenter, controlled trial involving 285 normotensive patients with type 1 diabetes and normoalbuminuria and who were randomly assigned to receive losartan (100 mg daily), enalapril (20 mg daily), or placebo and followed for 5 years. The primary end point was a change in the fraction of glomerular volume occupied by mesangium in kidney-biopsy specimens. The retinopathy end point was a progression on a retinopathy severity scale of two steps or more. Intention-to-treat analysis

NEJM2009 Full Text: Link to full Text with Trip Pro

15. Enalapril and captopril increased mortality compared with ramipril in elderly patients with heart failure

Enalapril and captopril increased mortality compared with ramipril in elderly patients with heart failure Enalapril and captopril increased mortality compared with ramipril in elderly patients with heart failure | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Enalapril and captopril increased mortality compared with ramipril in elderly patients with heart failure Article Text Causation Enalapril and captopril increased mortality compared with ramipril in elderly patients with heart failure Statistics from

Evidence-Based Nursing (Requires free registration)2008

16. Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril

Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril Wagner M, Rindress D, Desjardins B, Meilleur M C, Ducharme A, Tardif J C Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the impact of enalapril on the incidence of atrial fibrillation (AF) in patients with heart failure (HF). Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population

NHS Economic Evaluation Database.2005

17. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study.

Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. 12788569 2003 06 05 2003 07 03 2015 06 16 0140-6736 361 9372 2003 May 31 Lancet (London, England) Lancet Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. 1843-8 In the studies of left ventricular dysfunction (SOLVD), enalapril reduced mortality in patients with symptomatic (...) but not asymptomatic left ventricular systolic dysfunction during the trial. We did a 12-year follow-up of SOLVD to establish if the mortality reduction with enalapril among patients with heart failure was sustained, and whether a subsequent reduction in mortality would emerge among those with asymptomatic ventricular dysfunction. Of the 6797 patients previously enrolled in the SOLVD prevention and treatment trials, we ascertained the subsequent vital status of 5165 individuals who were alive when the trials had

Lancet2003

18. The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction

The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction Cook J R, Glick H A, Gerth W, Kinosian B, Kostis J B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of enalapril for the treatment of hypertensive patients with left ventricular dysfunction. Type of intervention Secondary prevention and treatment. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population The study population comprised patients who had

NHS Economic Evaluation Database.1998

19. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension.

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. 9486993 1998 03 05 1998 03 05 2013 11 21 0028-4793 338 10 1998 Mar 05 The New England journal of medicine N. Engl. J. Med. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. 645-52 It has recently been reported that the use of calcium-channel blockers (...) for hypertension may be associated with an increased risk of cardiovascular complications. Because this issue remains controversial, we studied the incidence of such complications in patients with non-insulin-dependent diabetes mellitus and hypertension who were randomly assigned to treatment with either the calcium-channel blocker nisoldipine or the angiotensin-converting-enzyme inhibitor enalapril as part of a larger study. The Appropriate Blood Pressure Control in Diabetes (ABCD) Trial is a prospective

NEJM1998

20. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group.

Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group. 9251545 1997 08 28 1997 08 28 2013 11 21 0959-8138 315 7101 1997 Jul 19 BMJ (Clinical research ed.) BMJ Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group. 154 (...) -9 To compare the effectiveness and tolerability of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in patients with mild to moderate hypertension. Randomised multicentre trial over 48 weeks with double blind comparison of treatments. 48 centres in four countries. 868 patients with essential hypertension (diastolic blood pressure 95-120 mm Hg) Initial treatment (step 1) consisted of 12.5 mg hydrochlorothiazide (n = 215), 25 mg atenolol (n = 215), 10 mg nitrendipine (n = 218), or 5 mg

BMJ1997 Full Text: Link to full Text with Trip Pro